Subex Q1 FY27 Earnings Call — Analysis (NSE: SUBEXLTD)
Subex posts strong Q1FY27 with 21.2% EBITDA margin and 19.7% revenue growth; management declares the turnaround complete and shifts focus to sustainable double-digit growth and AI-led product expansion.
The take
Q1FY27 Revenue ₹79.45 Cr ( +19.7% YoY ) . New guidance — quarterly revenue run-rate ₹100 Cr . New story: Turnaround complete, now scaling growth .
Results
Revenue ₹79.45 Cr +19.7% YoY (+8.9% QoQ); EBITDA ₹16.87 Cr (margin 21.2%); PAT ₹14.22 Cr (17.9% margin); cash ₹184.8 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹79.45 Cr | +19.7% | yoy · Q1FY27 |
| Revenue (sequential) | ₹79.45 Cr | +8.9% | qoq · Q1FY27 |
| EBITDA | ₹16.87 Cr | +4x | yoy · Q1FY27 · compared to same quarter last year |
| EBITDA margin | 21.2% | none · Q1FY27 · Q1FY27 | |
| PAT | ₹14.22 Cr | none · Q1FY27 · reported PAT including exceptional items | |
| PAT margin | 17.9% | none · Q1FY27 | |
| Cash & cash equivalents | ₹184.8 Cr | point_in_time · Q1FY27 · as of Jun-26 |
Guidance
Management aims for double-digit FY27 revenue growth, sees line-of-sight to ₹100 Cr quarterly revenue in a few quarters, and expects to sustain EBITDA margin in the mid-to-high teens while increasing R&D reinvestment.
What management committed to
- [Quarterly revenue] will reach ₹100 Cr in a few quarters. — ₹100 Cr, in a few quarters
- ESOP Trust will acquire up to 2% of equity shares from the market during FY27; execution expected around Q3FY27. — 2%, FY27
- [Litigation on old sectoral contracts] will be fully concluded by the end of FY27. — FY27
- Management will not infuse further capital into the Middle East subsidiary at this stage. — FY27
- FY27 EBITDA margin will be sustained in the mid-to-high teens range; additional cash will be reinvested rather than driving further margin expansion. — mid-to-high teens, FY27
- Quarterly non-deal roadshows (NDRs) will be conducted consistently going forward. — ongoing
- Implementation cycle time [for new projects] will be reduced by one quarter from the typical 4–5 quarters. — one quarter reduction
Key themes
Turnaround complete; accelerating growth through AI and PEM
How the narrative shifted
- Turnaround complete, now scaling growth: Management frames the last three years as simplification and restoration; FY27 is the first year of proving consistent, sustainable growth.
- PEM emerging as third growth engine: PEM (Partner Ecosystem Management) presented as an underinvested asset now delivering deal flow and renewals, adding diversification beyond RAFM.
- AI and GenAI product integration: Existing products are being conversational/GenAI-enabled; R&D spend will increase to ride new fraud vectors and adjacencies like data centres and satellites.
- Middle East geopolitical headwinds: Geopolitical tensions in the Middle East are causing contract closure delays of 1–2 months, though no cancellations; delivery moved offshore to mitigate.
- Capital market visibility push: Management initiates quarterly NDRs and plans broader city coverage to address investor perception gap and provide access beyond earnings calls.
- Healthy margins with disciplined reinvestment: Rather than maximising short-term margins, the company will maintain a healthy profile and plow excess cash into R&D and growth initiatives.
- Balance-sheet restructuring and ESOP: Capital reduction and ESOP market purchase under consideration/planned to align management and optimise the balance sheet.
Operational commentary
- PEM (Partner Ecosystem Management) gaining traction: secured renewal with Tier‑1 APAC operator, saw stronger deal flow; investments rebuilding team and roadmap now yielding results.
- Renewed managed services and software licence with a Tier‑1 Middle East operator despite regional geopolitical concerns; managed to pull back on‑site delivery to Bangalore to ensure continuity.
- Won new business assurance and fraud management deal with a leading European operator.
- FraudZap product achieved full ROI; new deal(s) delayed by about a month but expected to close soon.
- Implementation cycle shortened by ~45 days on a recent project; internal goal to cut overall time‑to‑subscription by one quarter.
- Initiated quarterly non‑deal roadshows (NDRs) to broaden capital‑market visibility; planning Mumbai, Ahmedabad, Chennai coverage.
- ESOP programme: board approved acquiring up to 2% from market in FY27; execution expected around Q3FY27 post shareholder approval.
- Middle East subsidiary now self‑sufficient; no further capital infusion planned at this time.
- Litigation on old sectoral contracts: one of three parties settled; hope to close the remaining two this quarter, fully resolved by FY27‑end.
- Revenue mix remains ~70% recurring from backlog, 30% from new wins; qualified pipeline maintained at 3–4x order‑intake target.
Analyst Q&A
Q. What is the size of the executable order pipeline for this year?
Cannot disclose a specific number because it is competitive-sensitive; pipeline directionally is at 3–4x qualified order intake target.
Q. What is the capital reduction/write-off timeline and process?
Strongly under consideration; will appoint a consultant, requires board, shareholder and NCLT approvals, so a long-term process.
Q. Where do you see EBITDA margins stabilising?
Should be in the current ballpark in the mid‑to‑high teens; we want a healthy margin profile and will reinvest excess for growth.
Q. What is the timeline for hitting ₹100 Cr quarterly revenue?
It should happen in a few quarters; we have line-of-sight based on the backlog.
Q. What is the minimum profit margin threshold below which you don’t take orders?
That is confidential and competition-sensitive, cannot disclose.
Q. How much of the ₹72 Cr to ₹79 Cr sequential revenue jump came from forex?
About ₹3 crores was currency gain.
Research and educational content only. Not investment advice.